Advertisement
Screener

Foghorn Therapeutics Inc. (FHTX) Borrowing debt

Foghorn Therapeutics Inc. (FHTX) Borrowing debt

  • Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2021-12-31..
  • Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2021-12-31..
  • Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2021-12-31..

Borrowing debt

Overview →

Financial period ending 2021-12-31; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Total debt · latest quarter (USD)(m)Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2021-12-31.

Calculation unavailable: missing inputs remain (m).

Net cash · latest quarter(m)Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2021-12-31.

Calculation unavailable: missing inputs remain (m).

Debt / assets · latest quarter(m)Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2021-12-31.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Borrowing debt due within one year(m)Long-term Debt, Current Maturities
Borrowing debt due after one year0.00 USDLong-term Debt, Excluding Current Maturities
Commercial paper(m)
Cash and current securities(m)Cash and Cash Equivalents, at Carrying Value
Borrowing debt(m)Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities
Total assets519.77M USDAssets

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingTotal debtNet cash / debtBorrowing debt due within one year (USD)Borrowing debt due after one year (USD)Commercial paper (USD)Cash and current securities (USD)Total assets (USD)Debt / assets
2021-12-31(m)(m)(m)$0.00(m)(m)$519.77M(m)
2021-09-30(m)(m)(m)$20.00M(m)(m)$186.07M(m)
2021-06-30(m)(m)(m)$20.00M(m)(m)$208.53M(m)
2021-03-31(m)(m)$0.00$20.00M(m)(m)$229.89M(m)
2020-12-31(m)(m)(m)$19.65M(m)(m)$255.59M(m)
2020-09-30(m)(m)$5.99M$8.80M(m)(m)$142.43M(m)
2019-12-31(m)(m)$4.15M$10.96M(m)(m)$22.34M(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
Nkarta, Inc. (NKTX)United States$0.205B-1.73
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37